For example, in a previous study, combining a peptide vaccine targeting the MAGE-A3 antigen with anti-PD-1 blockade in patients with melanoma resulted in increased T cell activity and improved clinical outcomes.466 The addition of checkpoint blockade reinvigorated exhausted T cells, allowing them to activate a more effective response against tumor cells. The gene discussed is PDCD1; the disease is neoplasm.